Tumor Biology

, Volume 37, Issue 6, pp 7939–7950 | Cite as

miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug

  • Zhihao Wu
  • Xiangli Li
  • Xuehong Cai
  • Chenggang Huang
  • Min Zheng
Original Article


Epithelial to mesenchymal transition (EMT) is a critical step in the growth and dissemination of malignant diseases, including breast cancer. It is known that microRNAs (miRNAs) play important roles in the regulation of tumor properties in cancers. However, whether miR-497 contributes to EMT in breast cancer cells remains unknown. Our study demonstrated that the expression of miR-497 was significantly decreased in human breast cancer cell lines and breast cancer specimens. In breast cancer cells, EMT was inhibited and promoted by the over-expression as well as depletion of miR-497, respectively. Dual-Luciferase ReporterAassay confirmed that Slug was a direct target of miR-497. The upregulation of miR-497 in breast cancer cells suppressed cell proliferation and induced apoptosis both in vitro and in vivo. Correlation analysis indicated that miR-497 was highly negatively correlated with Slug expression in breast cancer specimens. The knockdown of Slug expression in breast cancer cells significantly suppressed cell proliferation and promoted apoptosis. Our results suggested that the expression of miR-497 is significantly correlated with EMT in breast cancer cells by regulating Slug at the transcriptional as well as translational levels. Therefore, targeting miR-497 may provide a novel strategy for the treatment of breast cancer.


Breast cancer miR-497 EMT Slug Apoptosis 



epithelial to mesenchymal transition




untranslated regions


short interfering


quantitative reverse transcription polymerase chain reaction


terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling


cell counting kit-8


Compliance with ethical standards

Ethical statement

The ethic committee of The Second Affiliated Hospital & Yuying Children’ s Hospital of Wenzhou Medical University had approved this trial in October, 2012. Informed consent was obtained from all individual participants included in this study. This clinical trial had been registered on Clinical (NCT01336245).

Conflicts of interest



  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Beretov J, Wasinger VC, Millar EK, et al. Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach [J]. PLoS One. 2015;10(11):e0141876.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Soares RJ, Cagnin S, Chemello F, et al. Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions [J]. J Biol Chem. 2014;289(32):21909–25.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Godnic I, Zorc M, Jevsinek Skok D. Genome-wide and species-wide in silico screening for intragenic microRNAs in human, mouse and chicken. PLoS One. 2013;8(6):e65165.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gromak N, Dienstbier M, Macias S, et al. Drosha regulates gene expression independently of RNA cleavage function [J]. Cell Rep. 2013;5(6):1499–510.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Huang L, Wang X, Wen C, et al. Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer [J]. Sci Rep. 2015;5:13350.CrossRefPubMedGoogle Scholar
  7. 7.
    Bonet F, Dueñas Á, López-Sánchez C, et al. MiR-23b and miR-199a impair epithelial-to-mesenchymal transition during atrioventricular endocardial cushion formation [J]. Dev Dyn. 2015;244(10):1259–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Du M, Shi D, Yuan L, et al. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer [J]. Sci Rep. 2015;5:10437.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wei C, Luo Q, Sun X, et al. microRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer [J]. Int J Clin Exp Pathol. 2015;8(7):7729–39.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Troppan K, Wenzl K, Pichler M, et al. miR-199a and miR-497 Are associated with better overall survival due to increased chemosensitivity in diffuse large B-cell lymphoma patients [J]. Int J Mol Sci. 2015;16(8):18077–95.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Han Z, Zhang Y, Yang Q, et al. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1) [J]. Oncotarget. 2015;6(15):13149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xie Y, Wei RR, Huang GL, et al. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma [J]. Med Oncol. 2014;31(3):844.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu S, Fu GB, Tao Z, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1 [J]. Oncotarget. 2015;6(28):26457–71.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kordezangeneh M, Irani S, Mirfakhraie R, et al. Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles [J]. Med Oncol. 2015;32(7):208.CrossRefPubMedGoogle Scholar
  15. 15.
    Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook [J]. Annu Rev Biomed Eng. 2015;17:63–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Vijayarathna S, Gothai S, Jothy SL, et al. Can cancer therapy be achieved by bridging apoptosis and autophagy: a method based on microRNA-dependent gene therapy and phytochemical targets [J]. Asian Pac J Cancer Prev. 2015;16(17):7435–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Kamran N, Candolfi M, Baker GJ, et al. Gene therapy for the treatment of neurological disorders: central nervous system neoplasms [J]. Methods Mol Biol. 2016;1382:467–82.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Huang C, Ma R, Yue J. MiR-497 suppresses YAP1 and inhibits tumor growth in non-small cell lung cancer [J]. Cell Physiol Biochem. 2015;37(1):342–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang S, Mo Y, Midorikawa K, et al. The potent tumor suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal carcinoma by targeting ANLN and HSPA4L [J]. Oncotarget. 2015;6(34):35893–907.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Shen L, Li J, Xu L, et al. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w [J]. Exp Ther Med. 2012;3(3):475–80.PubMedGoogle Scholar
  21. 21.
    Qifeng L, Xiaoyu L, Yan G, et al. MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int. 2013;13:95.CrossRefGoogle Scholar
  22. 22.
    Li LD, Sun HF, Liu XX, et al. Down-regulation of NDUFB9 promotes breast cancer cell proliferation, metastasis by mediating mitochondrial metabolism [J]. PLoS One. 2015;10(12):e0144441.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang SC, Lin XL, Wang HY, et al. Hes1 triggers epithelial-mesenchymal transition (EMT)-like cellular marker alterations and promotes invasion and metastasis of nasopharyngeal carcinoma by activating the PTEN/AKT pathway [J]. Oncotarget. 2015;6(34):36713–30.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Li S, Qin X, Li Y, et al. MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4 [J]. Am J Transl Res. 2015;7(8):1390–403.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Lian SX, Shao YB, Liu HB, et al. PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer [J]. Oncotarget. 2015;6(30):29076–86.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Ishikawa K, He S, Terasaki H, et al. Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy [J]. Sci Rep. 2015;5:16386.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yu Y, Zhao Y, Sun XH, et al. Down-regulation of miR-129-5p via the Twist1 -Snail feedback loop stimulates the epithelial-mesenchymaltransition and is associated with poor prognosis in human breast cancer [J]. Oncotarget. 2015;6(33):34423–36.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Li Q, Peng J, Li X, et al. miR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-β-mediated EMT [J]. Diagn Pathol. 2015;10(1):202.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zheng M, Jiang YP, Chen W, et al. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma [J]. Oncotarget. 2015;6(9):6797–810.CrossRefPubMedGoogle Scholar
  30. 30.
    Lolli A, Lambertini E, Penolazzi L, et al. Pro-chondrogenic effect of miR-221 and slug depletion in human MSCs [J]. Stem Cell Rev. 2014;10(6):841–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Baldwin LA, Hoff JT, Lefringhouse J, et al. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget. 2014;5(23):12203–17.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Osaka E, Yang X, Shen JK, et al. MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug [J]. J Orthop Res. 2014;32(8):1075–82.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Li W, Jiang G, Zhou J, et al. Down-regulation of miR-140 induces EMT and promotes invasion by targeting Slug in esophageal cancer [J]. Cell Physiol Biochem. 2014;34(5):1466–76.CrossRefPubMedGoogle Scholar
  34. 34.
    Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms [J]. Oncogene. 2013;32(3):296–306.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zhihao Wu
    • 1
  • Xiangli Li
    • 1
  • Xuehong Cai
    • 2
  • Chenggang Huang
    • 2
  • Min Zheng
    • 1
    • 2
  1. 1.Department of Breast SurgeryThe Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical UniversityWenzhouChina
  2. 2.Department of General SurgeryThe First People Hospital of YueyangYueyangChina

Personalised recommendations